tbc-11251 has been researched along with Scleroderma, Systemic in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantatore, FP; Corrado, A; Costantino, E; Foschino Barbaro, MP; Neve, A; Palladino, GP | 1 |
| Coghlan, G; Kabunga, P | 1 |
| Becker, H; Domschke, W; Gaubitz, M; Mohr, M; Sunderkoetter, C; Willeke, P | 1 |
| Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
| Bellamy, CO; Dhaun, N; Kluth, DC; MacIntyre, IM | 1 |
| Derk, CT; Shetty, N | 1 |
| Hintz, E; Klein, R; Staehler, G | 1 |
| Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
| Brizzolara, R; Cutolo, M; Ferrone, C; Montagna, P; Parodio, A; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B | 1 |
2 review(s) available for tbc-11251 and Scleroderma, Systemic
| Article | Year |
|---|---|
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
7 other study(ies) available for tbc-11251 and Scleroderma, Systemic
| Article | Year |
|---|---|
Effect of endothelin inhibition on lung fibroblasts on patients with systemic sclerosis.
Topics: Actins; Adult; Aged; Cell Differentiation; Cell Survival; Collagen Type I; Endothelin Receptor Antagonists; Endothelins; Female; Fibroblasts; Fibronectins; Humans; Isoxazoles; Lung; Male; Middle Aged; Muscle, Smooth; Myofibroblasts; Scleroderma, Systemic; Thiophenes; Vascular Endothelial Growth Factor A | 2013 |
[Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy].
Topics: Adult; Antihypertensive Agents; Female; Humans; Isoxazoles; Leg Ulcer; Raynaud Disease; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2009 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.
Topics: Amides; Antihypertensive Agents; Atrophy; Biomarkers; Biopsy; Endothelin Receptor Antagonists; Female; Fibrosis; Fumarates; Humans; Hypertension, Renal; Isoxazoles; Kidney; Middle Aged; Proteinuria; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Renin; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2009 |
Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
Topics: Autoantibodies; Autoantigens; Disease Progression; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Hepatitis, Autoimmune; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2012 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients.
Topics: Aged; Bosentan; Cells, Cultured; Collagen Type I; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Extracellular Matrix Proteins; Female; Fibrillin-1; Fibrillins; Fibroblasts; Fibronectins; Fibrosis; Humans; Isoxazoles; Microfilament Proteins; Middle Aged; Primary Cell Culture; Scleroderma, Systemic; Sulfonamides; Thiophenes | 2012 |